Emad Shash, General Manager of the Breast Cancer Comprehensive Center of the National Cancer Institute at Cairo University, shared an article by Amira Mohamed Taha, et al. on LinkedIn:
“Exciting News!
Thrilled to share our latest systematic review and meta-analysis, published in Medicine, on the role of adjuvant radiotherapy (PORT) in postmenopausal women with early-stage ER-positive breast cancer!
Key Findings:
PORT significantly reduces local and regional recurrence in postmenopausal women with early-stage ER-positive, node-negative breast cancer.
However, PORT did not show a significant impact on distant relapse or overall survival.
What does this mean? We must carefully balance the benefits and risks of PORT to avoid overtreatment in low-risk patients.
This study provides valuable insights for clinical decision-making, supporting a personalized approach to breast cancer treatment.
Join the conversation!
Should adjuvant radiotherapy be standard for all, or should we refine selection criteria for treatment?
How do you approach de-escalation strategies in low-risk patients?
Grateful to my incredible co-authors Amira Mohamed Taha, Loay Kassem for this impactful work!
Let’s continue pushing the boundaries of evidence-based cancer care.”
Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis.
Authors: Amira Mohamed Taha, et al.
